Zacks Investment Research upgraded shares of Bioamber (NYSE:BIOA) from a sell rating to a hold rating in a research note issued to investors on Monday, February 19th.
According to Zacks, “BioAmber Inc. is a bio-based chemicals company. It produces and sells bio-succinic acid. The company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in products including plastics, resins, food additives and personal care products. It operates in France, China, Canada, and the United States. BioAmber Inc. is based in Plymouth, Minnesota. “
BIOA has been the topic of several other research reports. ValuEngine lowered Bioamber from a sell rating to a strong sell rating in a research note on Friday, December 1st. Cowen reissued a hold rating and set a $1.00 target price on shares of Bioamber in a research note on Friday, November 10th. Finally, HC Wainwright reaffirmed a buy rating and issued a $12.00 price target on shares of Bioamber in a research report on Wednesday, November 8th.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Robecosam AG increased its holdings in shares of Bioamber by 82.9% in the 3rd quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock valued at $741,000 after acquiring an additional 670,000 shares during the last quarter. FMR LLC grew its stake in Bioamber by 1.9% during the 2nd quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock worth $3,495,000 after buying an additional 25,000 shares during the last quarter. Vanguard Group Inc. grew its stake in Bioamber by 9.9% during the 2nd quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock worth $780,000 after buying an additional 27,278 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Bioamber by 336.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after buying an additional 41,701 shares during the last quarter. Institutional investors and hedge funds own 28.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Upgrades Bioamber (NYSE:BIOA) to “Hold”” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://stocknewstimes.com/2018/03/14/bioamber-bioa-upgraded-to-hold-at-zacks-investment-research-2.html.
Bioamber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.